| Protein selection using yeast surface display N Gera, M Hussain, BM Rao Methods 60 (1), 15-26, 2013 | 148 | 2013 |
| Highly stable binding proteins derived from the hyperthermophilic Sso7d scaffold N Gera, M Hussain, RC Wright, BM Rao Journal of Molecular Biology 409 (4), 601-616, 2011 | 104 | 2011 |
| Generation and properties of antibacterial coatings based on electrostatic attachment of silver nanoparticles to protein-coated polypropylene fibers KK Goli, N Gera, X Liu, BM Rao, OJ Rojas, J Genzer ACS Applied Materials and Interfaces, 2013 | 77 | 2013 |
| Design of pH Sensitive Binding Proteins from the Hyperthermophilic Sso7d Scaffold N Gera, AB Hill, DP White, RG Carbonell, BM Rao PLOS ONE 7 (11), e48928, 2012 | 77 | 2012 |
| Preservation of Cell Viability and Protein Conformation on Immobilization within Nanofibers via Electrospinning Functionalized Yeast MF Canbolat, N Gera, C Tang, B Monian, BM Rao, B Pourdeyhimi, ... ACS Applied Materials and Interfaces, 2013 | 39 | 2013 |
| A nanophosphor‐based method for selective DNA recovery in Synthosomes M Nallani, O Onaca, N Gera, K Hildenbrand, W Hoheisel, U Schwaneberg Biotechnology journal 1 (7‐8), 828-834, 2006 | 37 | 2006 |
| The evolution of bispecific antibodies N Gera Expert Opinion on Biological Therapy 22 (8), 945-949, 2022 | 20 | 2022 |
| Growth Kinetics and Production of Glucose Oxidase Using Aspergillus niger NRRL 326 N Gera, RVS Uppaluri, S Sen, VV Dasu Chemical and Biochemical Engineering Quarterly 22 (3), 315-320, 2008 | 19 | 2008 |
| Avidity‐mediated virus separation using a hyperthermophilic affinity ligand M Hussain, D Lockney, R Wang, N Gera, BM Rao Biotechnology Progress 29 (1), 237-246, 2013 | 12 | 2013 |
| Scaffold diversification enhances effectiveness of a super-library of hyperthermophilic proteins M Hussain, N Gera, AB Hill, BM Rao ACS Synthetic Biology, 2012 | 10 | 2012 |
| MYTX-011: A novel cMET-targeting antibody drug conjugate (ADC) engineered to increase on-target uptake in and efficacy against cMET expressing tumors N Gera, K Fitzgerald, V Ramesh, P Patel, L Kien, D Kanojia, S Aoyama, ... Cancer Res. 83 (Suppl. 7)), 5000, 2023 | 2 | 2023 |
| Yeast Display Guided Selection of pH-Dependent Binders JN Meanor, AJ Keung, BM Rao, N Gera Yeast Surface Display, 293-311, 2022 | 2 | 2022 |
| Polypeptides that bind complement component C5 or serum albumin and fusion proteins thereof B Puffer, J Chandler, N Gera, DL Sheridan, S Jindal, PP Tamburini US Patent 11,498,960, 2022 | 1 | 2022 |
| Biparatopic antibodies: therapeutic applications and prospects DL Niquille, KM Fitzgerald, N Gera mAbs 16 (1), 2310890, 2024 | | 2024 |
| MYTX-011: a pH-dependent anti-cMET antibody-drug conjugate designed for enhanced payload delivery to cMET expressing tumor cells N Gera, KM Fitzgerald, V Ramesh, P Patel, D Kanojia, F Colombo, L Kien, ... Molecular Cancer Therapeutics, 2024 | | 2024 |
| Anti-met antibodies and uses thereof BP Fiske, N Gera, AJ Nichols US Patent App. 18/510,256, 2024 | | 2024 |
| MYTX-011: A pH-dependent anti-cMET ADC with increased payload delivery in vivo and potent activity against cMET-expressing tumors of various epithelial origins D Kanojia, W Comb, W Israelsen, F Colombo, L Nie, N Gera, T Chittenden, ... Cancer Research 84 (6_Supplement), 1907-1907, 2024 | | 2024 |
| Characterization of the bispecific VHH antibody gefurulimab (ALXN1720) targeting complement component 5, and designed for low volume subcutaneous administration S Jindal, DV Pedersen, N Gera, J Chandler, R Patel, A Neill, J Cone, ... Molecular Immunology 165, 29-41, 2024 | | 2024 |
| MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression WC Comb, D Kanojia, F Colombo, V Ramesh, N Gera, T Chittenden, ... MOLECULAR CANCER THERAPEUTICS 22 (12), 2023 | | 2023 |
| Abstract B124: MYTX-011 is a highly internalized ADC with anti-tumor activity across a spectrum of NSCLC preclinical models with various levels of cMET expression WC Comb, D Kanojia, F Colombo, V Ramesh, N Gera, T Chittenden, ... Molecular Cancer Therapeutics 22 (12_Supplement), B124-B124, 2023 | | 2023 |
Balaji (Bala) RaoProfessor of Chemical and Biomolecular Engineering, NC State UniversityVerified email at ncsu.edu
